Wen-Peng Zhao1, Zhi-Yu Han2, Jing Zhang2, Xiao-Ling Yu2, Zhi-Gang Cheng2, Xiang Zhou1, Ping Liang2. 1. Department of Ultrasound, National Cancer Center; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China.
Abstract
OBJECTIVE: The study was conducted to describe ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in the treatment of intra-abdominal aggressive fibromatosis in seven patients who had failed surgery. METHODS: We retrospectively investigated seven patients with pathologically proven intra-abdominal aggressive fibromatosis and surgical failure, who were treated with USgHIFU between June 2013 and February 2015. The main causes for surgical failure were a large tumour size or adjacent tissue invasion by the tumour. All of the patients were treated with palliative intent, to reduce symptoms of the diseases. The medical records were reviewed during the follow-up period, and the patients were asked to compare the symptoms of their disease as improved, unchanged or worsened, based on their levels before treatment. In addition, contrast-enhanced MRI was conducted to follow the size of the tumours before and after therapy. RESULTS: The procedure was successfully accomplished in all of the patients without severe side effects. The median diameter of the tumours was 10.3 cm (range, 7.6-13.6 cm) and the mean ablation rate (the percentage rate of the non-perfused volume compared with the tumour volume on enhanced MRI after treatment) was 92.5 ± 3.7% (range, 86.5-96.8%). One patient underwent two treatments for a large tumour size, and other patients received single-visit therapy. All of the patient clinical symptoms remitted significantly after 6 months. The regression rates of the tumours were 34.8 ± 8.2% (range, 22.4-46.1%) and 58.2 ± 12.7% (range, 43.8-70.3%), respectively, at 6 and 12 months after treatment. CONCLUSION: USgHIFU ablation could be an effective alternative minimally invasive therapy for the achievement of local control of intra-abdominal aggressive fibromatosis. ADVANCES IN KNOWLEDGE: The conclusions indicate that USgHIFU ablation could be a promising alternative treatment for the achievement of local control of intra-abdominal aggressive fibromatosis.
OBJECTIVE: The study was conducted to describe ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in the treatment of intra-abdominal aggressive fibromatosis in seven patients who had failed surgery. METHODS: We retrospectively investigated seven patients with pathologically proven intra-abdominal aggressive fibromatosis and surgical failure, who were treated with USgHIFU between June 2013 and February 2015. The main causes for surgical failure were a large tumour size or adjacent tissue invasion by the tumour. All of the patients were treated with palliative intent, to reduce symptoms of the diseases. The medical records were reviewed during the follow-up period, and the patients were asked to compare the symptoms of their disease as improved, unchanged or worsened, based on their levels before treatment. In addition, contrast-enhanced MRI was conducted to follow the size of the tumours before and after therapy. RESULTS: The procedure was successfully accomplished in all of the patients without severe side effects. The median diameter of the tumours was 10.3 cm (range, 7.6-13.6 cm) and the mean ablation rate (the percentage rate of the non-perfused volume compared with the tumour volume on enhanced MRI after treatment) was 92.5 ± 3.7% (range, 86.5-96.8%). One patient underwent two treatments for a large tumour size, and other patients received single-visit therapy. All of the patient clinical symptoms remitted significantly after 6 months. The regression rates of the tumours were 34.8 ± 8.2% (range, 22.4-46.1%) and 58.2 ± 12.7% (range, 43.8-70.3%), respectively, at 6 and 12 months after treatment. CONCLUSION: USgHIFU ablation could be an effective alternative minimally invasive therapy for the achievement of local control of intra-abdominal aggressive fibromatosis. ADVANCES IN KNOWLEDGE: The conclusions indicate that USgHIFU ablation could be a promising alternative treatment for the achievement of local control of intra-abdominal aggressive fibromatosis.
Authors: S S Kamath; J T Parsons; R B Marcus; R A Zlotecki; M T Scarborough Journal: Int J Radiat Oncol Biol Phys Date: 1996-09-01 Impact factor: 7.038
Authors: Tan To Cheung; Sheung Tat Fan; Ferdinand S K Chu; Caroline R Jenkins; Kenneth S H Chok; Simon H Y Tsang; Wing Chiu Dai; Albert C Y Chan; See Ching Chan; Thomas C C Yau; Ronnie T P Poon; Chung Mau Lo Journal: HPB (Oxford) Date: 2012-12-04 Impact factor: 3.647
Authors: Igino Simonetti; Federico Bruno; Roberta Fusco; Carmen Cutolo; Sergio Venanzio Setola; Renato Patrone; Carlo Masciocchi; Pierpaolo Palumbo; Francesco Arrigoni; Carmine Picone; Andrea Belli; Roberta Grassi; Francesca Grassi; Antonio Barile; Francesco Izzo; Antonella Petrillo; Vincenza Granata Journal: J Pers Med Date: 2022-07-16